Pharmaceuticals
Teva Pharmaceutical Industries' $700 million acquisition of Emalex Biosciences brings ecopipam, a first-in-class D1 receptor antagonist, to pediatric Tourette syndrome treatment—challenging decades of dopamine D2-targeting therapy.
Biotechnology
Intellia Therapeutics announced positive Phase 3 results from the HAELO trial, marking the first time a Phase 3 clinical trial of an in vivo CRISPR-based gene editing therapy has reported positive outcomes.
Biotechnology
On April 23, 2026, the FDA granted accelerated approval to Regeneron's Otarmeni, the first gene therapy ever approved for genetic hearing loss—a breakthrough that represents a categorical shift in what medicine can do.
Biotechnology
Kyverna Therapeutics presented groundbreaking KYSA-8 trial data showing that a single CAR-T cell infusion could achieve what years of immunosuppression cannot: a durable immune reset in stiff person syndrome patients, potentially opening an entirely new therapeutic category for autoimmune diseases.
Biotechnology
Regeneron's Phase 3 NIMBLE trial data for cemdisiran demonstrates a paradigm shift in myasthenia gravis treatment. A quarterly subcutaneous injection achieves meaningful clinical outcomes with a favorable safety profile, potentially redefining patient care in this chronic neuromuscular disorder.
Policy
Trump's executive order fast-tracking FDA review of psychedelic drugs like psilocybin and ibogaine signals a major shift for mental health treatment and the biotech sector.
Biotechnology
Kailera Therapeutics' record-breaking $625 million IPO marks a pivotal moment in the obesity drug market, signaling investor confidence in Chinese-origin drug pipelines and validating a new model for biotech fundraising.
Biotechnology
Novartis CEO Vas Narasimhan's appointment to Anthropic's board marks a significant shift in pharmaceutical industry governance of AI technology, signaling that pharma is becoming a co-author of AI governance norms.
Biotechnology
Spyre Therapeutics' Phase 2 data for SPY001 demonstrates a credible challenge to Takeda's Entyvio blockbuster, with superior remission rates and the potential for quarterly or biannual dosing in ulcerative colitis treatment.
Biotechnology
Revolution Medicines' pan-RAS inhibitor daraxonrasib delivered a median overall survival of 13.2 months in metastatic pancreatic cancer—nearly doubling survival compared to standard chemotherapy. This Phase 3 breakthrough could reshape treatment paradigms for RAS-driven cancers.
Pharmaceuticals
The FDA faces its PDUFA deadline today on Travere Therapeutics' FILSPARI (sparsentan) for FSGS. If approved, it would be the first-ever therapy indicated for this rare, devastating kidney disease affecting 40,000 Americans.
Biotechnology
Gilead Sciences is acquiring German ADC biotech Tubulis for up to $5 billion, its third major oncology deal in 2026. The transaction reveals why antibody-drug conjugates have become the most fiercely contested technology platform in cancer drug development.